KYTTARO THERAPEUTICS

Kyttaro Therapeutics is a development-stage platform technology company with a unique patent portfolio in clinical applications of genetically modified MSCs for treatment of diseases with a high, unmet clinical need... Kyttaro Therapeutics was incorporated in the US (Delaware corporation) in 2021 to commercialize technologies developed by the founders of Apceth Biopharma GmbH since 2007. The company is headquartered in New York, with research operations in Germany... Kyttaro's expertise and intellectual property are based on 15 years of research and development in Germany and around the world in cutting-edge applications for MSC Alpha-1 Antitrypsin (MSC-AAT), MSC Cytokines (MSC-Cyt) and MSC-Klotho.

Also known as: Kyttaro, Kyttaro Therapeutics, Inc.

Primary location: New York United States